Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Martin Hjorth(Integrated Cardio Metabolic Centre), Peter Gimsing(University of Copenhagen), Rolf Billström(University of Skövde), Karin Forsberg, Annika Othzén(Gävle Hospital), Øyvind Hjertner(Norwegian University of Science and Technology), Torbjörn Karlsson, Max Flogegård(Falun Hospital), Hareth Nahi(Karolinska University Hospital), Björn Andréasson(NU Hospital Group), Per Trøllund Pedersen(Odense University Hospital), Kristina Carlson(Uppsala University Hospital), Nina Gulbrandsen(Oslo University Hospital), Erik Holmberg(University of Gothenburg), Olle Linder(Örebro University Hospital), Niels Frost Andersen(Aarhus University Hospital), Margaretha S. Carlsson(Växjö Kommun), Agneta Swedin(Skåne University Hospital), Lene Meldgaard Knudsen(Odense University Hospital)
Cited by 45
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
|New England Journal of Medicine|1997|611
Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months
|Journal of Thrombosis and Haemostasis|2006|507